We are live on !
Find out more
Rangeley Capital Portfolio holdings
AUM
$109M
Turnover
49.06%
1-Year Est. Return
97.13%
This Fund
S&P 500
This Quarter Est. Return
+34.11%
1 Year Est. Return
+97.13%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
+$6.53M
(+6.3%)
Cap. Flow
-$6.26M
Cap. Flow % of AUM
Cap. Flow %
-5.72%
Top 10 Holdings %
Top 10 Hldgs %
32.08%
Holding
212
New
75
Increased
28
Reduced
43
Closed
29
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.3
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nomad Foods
NOMD
|
+$1.34M |
| 2 |
Mountain Lake Acquisition Corp II
MLAA
|
+$1.27M |
| 3 |
Distribution Solutions Group
DSGR
|
+$1.26M |
| 4 |
enGene Therapeutics
ENGN
|
+$1.24M |
| 5 |
Abivax
ABVX
|
+$1.02M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$8.47M |
| 2 |
Leggett & Platt
LEG
|
+$2.1M |
| 3 |
Icon
ICLR
|
+$1.96M |
| 4 |
Kezar Life Sciences
KZR
|
+$1.8M |
| 5 |
Mister Car Wash
MCW
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.11% |
| 2 | Consumer Discretionary | 14.33% |
| 3 | Financials | 12.51% |
| 4 | Miscellaneous | 10.11% |
| 5 | Real Estate | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Boundless Bio
BOLD
$55.7M
| $185K | 0.17% |
+74,000
| New | +$114K |
2026 Q2
0 quarters
|
|
|
EMIS
127
Emmis Acquisition Corp
EMIS
$162M
| $183K | 0.17% |
18,107
| – | – |
2025 Q4
2 quarters
|
|
128
Apex Treasury Corp
APXT
$466M
| $178K | 0.16% |
+17,701
| New | +$177K |
2026 Q2
0 quarters
|
|
129
Alight
ALIT
$228M
| $176K | 0.16% |
15,745
+13,272
| +537% | +$188K |
2026 Q1
1 quarter
|
|
|
BCARU
130
DELISTED
D. Boral ARC Acquisition I Corp Units
BCARU
| $173K | 0.16% |
15,239
-57,191
| -79% | -$661K |
2025 Q3
3 quarters
|
|
131
Nkarta
NKTX
$131M
| $170K | 0.16% |
60,000
-8,000
| -12% | -$22.5K |
2025 Q4
2 quarters
|
|
132
Berto Acquisition Corp Warrant
TACOW
$9.35M
| $168K | 0.15% |
16,000
+500
| +3% | +$270 |
2026 Q1
1 quarter
|
|
133
Kyivstar Group
KYIV
$3.03B
| $162K | 0.15% |
10,000
| – | – |
2026 Q1
1 quarter
|
|
134
FACT II Acquisition Corp
FACT
$262M
| $158K | 0.14% |
14,886
-624
| -4% | -$6.62K |
2026 Q1
1 quarter
|
|
135
DELISTED
DigitalBridge
DBRG
| $158K | 0.14% |
10,000
| – | – |
2025 Q4
2 quarters
|
|
|
BBCQ
136
DELISTED
Bleichroeder Acquisition Corp II
BBCQ
| $155K | 0.14% |
+15,000
| New | +$155K |
2026 Q2
0 quarters
|
|
137
CALL
Rapid7
RPD
$1.21B
| $151K | 0.14% |
+18,700
| New | +$124K |
2026 Q2
0 quarters
|
|
138
International Money Express
IMXI
$277M
| $144K | 0.13% |
10,000
| – | – |
2025 Q3
3 quarters
|
|
139
HCM III Acquisition Corp
HCMA
$347M
| $144K | 0.13% |
14,046
+1,516
| +12% | +$15.5K |
2025 Q3
3 quarters
|
|
140
PMV Pharmaceuticals
PMVP
$60.4M
| $133K | 0.12% |
99,240
+32,394
| +48% | +$41.6K |
2025 Q3
3 quarters
|
|
141
Allogene Therapeutics
ALLO
$418M
| $128K | 0.12% |
+61,500
| New | +$135K |
2026 Q2
0 quarters
|
|
142
PepGen
PEPG
$172M
| $126K | 0.12% |
70,000
+1,904
| +3% | +$3.1K |
2025 Q1
5 quarters
|
|
|
TWO
143
DELISTED
Two Harbors Investment
TWO
| $124K | 0.11% |
10,000
| – | – |
2026 Q1
1 quarter
|
|
|
BRNS
144
DELISTED
Barinthus Biotherapeutics
BRNS
| $122K | 0.11% |
185,136
+25,671
| +16% | +$16.7K |
2025 Q4
2 quarters
|
|
|
145
Berto Acquisition Corp
TACO
$393M
| $121K | 0.11% |
+11,538
| New | +$120K |
2026 Q2
0 quarters
|
|
146
ImageneBio Inc
IMA
$46M
| $119K | 0.11% |
20,090
-12,500
| -38% | -$70.6K |
2025 Q3
3 quarters
|
|
147
FMC
FMC
$717M
| $115K | 0.11% |
10,000
| – | – |
2026 Q1
1 quarter
|
|
|
RAAQ
148
DELISTED
Real Asset Acquisition Corp
RAAQ
| $108K | 0.1% |
10,000
| – | – |
2025 Q4
2 quarters
|
|
149
Mereo BioPharma
MREO
$43.9M
| $105K | 0.1% |
329,200
| – | – |
2025 Q4
2 quarters
|
|
150
Sizzle Acquisition Corp II
SZZL
$329M
| $104K | 0.09% |
10,000
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
S2L
Rangeley Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Rangeley Capital held 212 positions worth $109M, up 6.3% from $103M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Rangeley Capital withdrew a net $6.26M in Q2 2026, closing 29 positions and reducing 43 holdings. Its most notable exit was Leggett & Platt, an estimated $2.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 29% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Rangeley Capital opened a new position in Nomad Foods worth $1.48M.
- Rangeley Capital's largest Q2 2026 buy was Nomad Foods: 135,000 shares worth $1.48M.
- Rangeley Capital added most to Distribution Solutions Group in Q2 2026, an estimated $1.26M increase.
- Rangeley Capital's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $8.47M.
- Rangeley Capital fully exited Leggett & Platt in Q2 2026, selling an estimated $2.1M.
- Rangeley Capital's ten largest holdings make up 32% of its $109M portfolio in Q2 2026.
- Rangeley Capital opened 75 new positions and closed 29 in Q2 2026.
- Rangeley Capital's portfolio value rose 6.3% quarter-over-quarter to $109M.
Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.